PRIVISCL — Privi Speciality Chemicals Income Statement
0.000.00%
- IN₹95.70bn
- IN₹106.68bn
- IN₹21.01bn
Annual income statement for Privi Speciality Chemicals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 12,766 | 14,037 | 16,078 | 17,522 | 21,012 |
Cost of Revenue | |||||
Gross Profit | 4,425 | 4,625 | 4,824 | 5,899 | 8,164 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 11,169 | 12,792 | 15,297 | 15,504 | 17,794 |
Operating Profit | 1,597 | 1,245 | 781 | 2,018 | 3,218 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,582 | 1,328 | 310 | 1,299 | 2,545 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,169 | 974 | 213 | 954 | 1,848 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1,169 | 974 | 222 | 949 | 1,870 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,169 | 974 | 222 | 949 | 1,870 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 25.6 | 23.9 | 5.79 | 23.9 | 47.9 |
Dividends per Share |